GlassScriptPhysician profile
Vishal Datta
NPI 1982654489
$334,224.67
in general payments reported to CMS, 2019-2025
13 companies · $57K in 2025
The $57K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $51K · 2021: $71K · 2022: $67K · 2023: $15K · 2024: $19K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Travel and Lodging: $8,260 · Food and Beverage: $2,845 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $79,615.19 |
| Travel and Lodging | $8,260.10 |
| Food and Beverage | $2,845.02 |
| Education | $239.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $331,897.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $473.19 | 2021-2025 | Mounjaro, Jardiance, Lyumjev |
| Medtronic, INC. | $384.13 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Genzyme Corporation | $362.00 | 2019-2020 | |
| Medtronic Minimed, INC. | $290.78 | 2019-2020 | |
| Corcept Therapeutics | $268.04 | 2024-2025 | Korlym |
| Abbvie INC. | $170.35 | 2019-2025 | |
| Abbott Laboratories | $108.74 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $101.48 | 2019 | |
| Sanofi-Aventis U.S. LLC | $90.62 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $51.45 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Antares Pharma, INC. | $14.80 | 2024 | Xyosted |
| Tandem Diabetes Care, INC. | $11.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishal Datta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.